Lawrence S. Kirschner

Lawrence S. Kirschner

Auto-generated profile, based on publicly available information

Lawrence S. Kirschner

Clinical Research Branch, National Institute of Environmental Health Sciences , Research Triangle Park, NC 27709 , USA

Research Focus & Metrics

Academic Career Length

30Years (1997-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 September 2009 in Endocrine-Related Cancer
Verified
Journal Article
Open access
PDF file
LKLawrence S Kirschner
Lawrence S Kirschner
ZYZhirong Yin
Zhirong Yin
GJGeorgette N Jones
Georgette N Jones
EMEmilia Mahoney
Emilia Mahoney
Protein kinase A (PKA) is an evolutionarily conserved protein which has been studied in model organisms from yeast to man. Although the cAMP–PKA signaling system was the first mammalian second messenger system to be characterized, many aspects of this pathway are still not well understood. Owing to findings over the past decade implicating PKA signaling in endocrine (and other) tumorigenesis, there has been renewed interest in understanding the role of this pathway in physiology, particularly as it pertains to the endocrine system. Because of the availability of genetic tools, mouse modeling has become the pre-eminent system for studying the physiological role of specific genes and gene families as a means to understanding their relationship to human diseases. In this review, we will summarize the current data regarding mouse models that have targeted the PKA signaling system. These data have led to a better understanding of both the complexity and the subtlety of PKA signaling, and point the way for future studies, which may help to modulate this pathway for therapeutic effect.

1 September 2003
Verified
Journal Article
Closed access
JBJerome Bertherat
Jerome Bertherat
LGLionel Groussin
Lionel Groussin
FSFabiano Sandrini
Fabiano Sandrini
LMLudmila Matyakhina
Ludmila Matyakhina
TBThalia Bei
Thalia Bei
CSConstantine A Stratakis
Constantine A Stratakis

1 January 2006 in The Journal of Clinical Endocrinology & Metabolism
Verified
Journal Article
Closed access
LKLawrence S. Kirschner
Lawrence S. Kirschner
Adrenocortical carcinoma (ACC) is a rare cancer but one that has devastating consequences for affected patients. Surgery is the mainstay of therapy, although the high frequency of metastatic disease implies that it is frequently noncurative. Traditional cytotoxic chemotherapy for ACC has generally produced disappointing responses, implying the need for the new therapies for this disease. Review articles and primary literature were identified by extensive PubMed searching to obtain papers evaluating the current state of knowledge regarding ACC, as well as assessing the development of new therapeutic modalities for the treatment of cancer. When needed, additional articles were identified from the reference lists of the papers obtained from the primary screen. Multiple new modalities that may enhance the future treatment of ACC were identified. They include the following: combating drug resistance, targeting tumor vasculature, inhibiting signaling pathways with small molecules, and using gene and/or immunotherapy. This review provides a brief summary of the progress and prospects of each of these modalities and focuses on emerging data and treatments that may alter the course of this disease within the next few years. Despite the current grim outlook, the recent applications of emerging technology to the study of ACC and the development of newer, "targeted" therapies for cancer suggest the possibility of a new hope for patients with this disease, although these therapies will need to be evaluated by rigorous clinical trials to verify their effectiveness.

27 July 2018 in Journal of the Endocrine Society
Verified
Journal Article
Open access
PDF file
PNPratima Nayak
Pratima Nayak
AMAlaa S Montaser
Alaa S Montaser
Jie HuJie Hu
Jie Hu
DPDaniel M Prevedello
Daniel M Prevedello
LKLawrence S Kirschner
Lawrence S Kirschner
LGLuma Ghalib
Luma Ghalib
Context The development of diabetes insipidus (DI) following transsphenoidal resection of pituitary adenomas has been associated with higher postsurgical morbidity and longer hospitalizations. Identifying these patients promptly and efficiently can lead to improved healthcare outcomes. Objective We evaluated our institution’s incidence of DI following pituitary adenoma resection and assessed for preoperative risk factors that were associated with postoperative DI. Design A retrospective review of 271 patients who underwent endoscopic endonasal resection of a pituitary adenoma between July 2010 and December 2016 by a single neurosurgical provider was completed. Setting All cases were from a single center, academic institution. Patients Patients with a pituitary adenoma diagnosis confirmed on histology were included in the study. Those with previous surgery by a different provider were excluded. Results The incidence of DI at our institution was 16.6% (45 of 271 patients) with only 4% (11 patients) having permanent DI. The presence of visual abnormalities (CI 1.29-4.75), suprasellar extension (CI 1.36-6.88), and maximal tumor diameter (1.02-1.08) were significantly associated with an increased incidence of postoperative DI (p < 0.05). Hyperprolactinemia, tumor functionality and CSF exposure were not associated with higher rates of postoperative DI (p > 0.05). Conclusion Pituitary adenoma patients presenting with visual abnormalities, suprasellar extension or large tumors are at higher risk of developing DI postoperatively. These patients warrant closer postoperative monitoring as well as adequate preoperative counseling to decrease their postsurgical morbidity.

8 May 2009 in EMBO Reports
Verified
Journal Article
Open access
PDF file
KNKiran S Nadella
Kiran S Nadella
MSMotoyasu Saji
Motoyasu Saji
NJNaduparambil K Jacob
Naduparambil K Jacob
EPEmilia Pavel
Emilia Pavel
MRMatthew D Ringel
Matthew D Ringel
LKLawrence S Kirschner
Lawrence S Kirschner
Proper regulation of the cAMP‐dependent protein kinase (protein kinase A, PKA) is necessary for cellular homeostasis, and dysregulation of this kinase is crucial in human disease. Mouse embryonic fibroblasts (MEFs) lacking the PKA regulatory subunit Prkar1a show altered cell morphology and enhanced migration. At the molecular level, these cells showed increased phosphorylation of cofilin, a crucial modulator of actin dynamics, and these changes could be mimicked by stimulating the activity of PKA. Previous studies of cofilin have shown that it is phosphorylated primarily by the LIM domain kinases Limk1 and Limk2, which are under the control of the Rho GTPases and their downstream effectors. In Prkar1a−/− MEFs, neither Rho nor Rac was activated; rather, we showed that PKA could directly phosphorylate Limk1 and thus enhance the phosphorylation of cofilin. These data indicate that PKA is crucial in cell morphology and migration through its ability to modulate directly the activity of LIM kinase.

1 February 2008 in Molecular Endocrinology
Verified
Journal Article
Open access
PDF file
ZYZhirong Yin
Zhirong Yin
LWLisa Williams-Simons
Lisa Williams-Simons
APA. F. Parlow
A. F. Parlow
Sylvia L. AsaSylvia L. Asa
Sylvia L. Asa
LSLawrence S. Lawrence S.
Lawrence S. Lawrence S.
Carney complex (CNC) is an inherited neoplasia syndrome characterized by spotty skin pigmentation, myxomas, endocrine tumors, and schwannomas. Among the endocrine tumors that comprise the syndrome, GH-producing pituitary tumors are seen in approximately 10% of patients, although biochemical abnormalities of the GH axis are much more common. To explore the role of loss of the CNC gene PRKAR1A on pituitary tumorigenesis, we produced a tissue-specific knockout (KO) of this gene in the mouse. For these studies, we generated a mouse line expressing the cre recombinase in pituitary cells using the rat GHRH receptor promoter. These mice were then crossed with Prkar1a conditional null animals to produce tissue-specific KOs. Although prolactinomas were observed in KO and control mice, the KO mice exhibited a significantly increased frequency of pituitary tumors compared with wild-type or conventional Prkar1a+/− mice. Characterization of the tumors demonstrated they were composed of cells of the Pit1 lineage that stained for GH, prolactin, and TSH. At the biochemical level, levels of GH in the serum of KO animals were markedly elevated compared with controls, regardless of the presence of a frank tumor. These data indicate that complete loss of Prkar1a is sufficient to allow the formation of pituitary tumors and abnormalities of the GH axis, in close analogy to human patients with CNC.